Our discovery of ACT, a first-of-its-kind immunotoxin platform that retains the modularity and versatility of DT, is superior to DT in its ability to delivery heterologous cargos into cells; but, does not suffer from issues associated with pre-existing ADA, represents a promising new approach to usher in a new generation of immunotoxins with improved properties for cancer therapy. Here, ADA is linked to cancer.